Pitcairn’s Esperion Therapeutics ESPR Stock Holding History

Pitcairn’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,847	Closed	-$18.8K	–	659
2023 Q1	$18.8K	Buy	+11,847	New	+$61.2K	﹤0.01%	600

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Pitcairn's ESPR Position: Q2 2023 in Review

Pitcairn sold out of Esperion Therapeutics (ESPR) in Q2 2023, closing a stake of 11,847 shares — an estimated $18.8K sold.

Pitcairn first reported a position in ESPR in Q1 2023 and held it in 1 quarter. The position peaked at $18.8K in Q1 2023. 124 funds tracked by Wall St. Rank hold ESPR as of Q2 2023.

Pitcairn reported no remaining Esperion Therapeutics position as of Q2 2023 after selling out during the quarter.
Pitcairn sold 11,847 Esperion Therapeutics shares in Q2 2023, an estimated $18.8K.
Pitcairn first reported a position in Esperion Therapeutics in Q1 2023 and held it in 1 quarter.
Pitcairn's Esperion Therapeutics position peaked at $18.8K in Q1 2023.
124 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2023.

Based on Pitcairn's 13F filing for Q2 2023, filed 11 Aug 2023.